IFF reaffirms 2025 sales guidance at $10.6B–$10.9B amid portfolio overhaul

Key Highlights from IFF's Q2 2025 Earnings Call

International Flavors & Fragrances Inc. (IFF) delivered a strong performance in the second quarter of 2025, with management emphasizing continued progress in growth, profitability, and strategic divestitures. CEO Jon Erik Fyrwald highlighted that the company’s net debt-to-EBITDA ratio has dropped to 2.5x, reflecting improved financial health. This was achieved through the completion of divestitures in the Pharma Solutions and Nitrocellulose businesses, a debt tender offer, and the announcement of a new $500 million share repurchase program.

Fyrwald noted that the company achieved solid growth and profitability in the first half of 2025, with 3% sales growth and 7% adjusted operating EBITDA growth. Additionally, the sale of the Soy Crush, Concentrates, and Lecithin business to Bunge was described as another step in the company’s focus on products with differentiated innovation that enhance margins.

Financial Performance Overview

CFO Michael DeVeau provided detailed insights into the company’s financial results for Q2. IFF reported second-quarter sales of just over $2.75 billion, representing a 3% year-over-year increase. Sales growth was seen across all businesses, primarily driven by volume gains, including mid-single-digit growth in Taste and Health & Biosciences. Adjusted operating EBITDA reached $552 million, marking a 6% increase and a 50 basis point improvement in margin compared to the same period last year.

Year-to-date cash flow from operations totaled $368 million, with capital expenditures at $274 million. Free cash flow in Q2 was $94 million. The company also reduced its gross debt to $6.2 billion as of June 30, down more than $3 billion from a year ago, with cash and cash equivalents at $816 million. This reduction helped the company achieve its net debt-to-EBITDA target of 2.5x in Q2.

Outlook for 2025

DeVeau reiterated full-year 2025 guidance, stating that IFF expects sales to range between $10.6 billion and $10.9 billion. While the dollar range remains consistent with prior expectations, it now reflects modestly softer volume expectations partially offset by favorable currency movements. Adjusted operating EBITDA for 2025 is expected to be between $2 billion and $2.15 billion, reflecting currency-neutral growth of 5% to 10%.

Management anticipates that growth will moderate in the second half of the year, particularly in Q3 due to a very strong year-over-year comparison. Despite an increasingly challenging operating environment, the company remains confident in its ability to meet full-year 2025 guidance.

Segment Performance and Strategic Focus

The company’s segment performance showed mixed results. Taste sales reached $631 million, up 6%, while Food Ingredients sales were $850 million, representing a 1% increase. Health & Biosciences grew by 4%, and Scent sales reached $603 million, up 1%. Adjusted operating EBITDA for Q2 was $552 million, with a 50 basis point increase in margin year-over-year.

Strategic divestitures have been a key focus for IFF. The sale of the Soy Crush, Concentrates, and Lecithin business to Bunge was highlighted as a move to streamline the portfolio and improve margins in the Food Ingredients business. Management also indicated that they are evaluating the Food Ingredients business further, with plans to provide updates during the fourth quarter earnings call.

Challenges and Risks

Despite positive financial results, management acknowledged several challenges. DeVeau pointed out weakening trends in the Health & Biosciences segment, with negative growth expected in Q3, specifically driven by health-related factors. Commodity pressures in the Fragrance Ingredients segment continue to pose a challenge, though the company is focusing on specialty molecule innovation to restore growth.

Analysts raised concerns about the sustainability of margin improvements, the timeline for the Food Ingredients strategic review, and the impact of divestitures on stranded costs. Management remained confident but cautious, noting that the second half of the year will be more challenging.

Strategic Moves and Future Outlook

IFF has emphasized capital allocation discipline, introducing a new $500 million share repurchase program and addressing stranded costs associated with divestitures. The company is also focused on portfolio simplification, with ongoing efforts to strengthen its position in higher-margin businesses.

The board has undergone recent changes, with new appointments aimed at enhancing governance, market experience, and innovation capabilities. Fyrwald expressed confidence in the team’s ability to navigate evolving conditions and drive the company forward.

Final Thoughts

Overall, IFF remains on track to meet its 2025 financial targets, supported by portfolio streamlining, disciplined capital allocation, and ongoing R&D investments. While near-term challenges persist, the company is positioning itself for improved execution in 2026 and beyond.